← Back to Search

Visual Remapping for Age-Related Macular Degeneration

N/A
Recruiting
Led By Stephen Engel, Ph.D.
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Stable fixation (+/- 1 deg) using their PRL.
16 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
Awards & highlights

Study Summary

This trial will test how well people with central vision loss can read with and without different kinds of remapping of missing text to different parts of the visual field, compared to people with no vision loss.

Who is the study for?
This trial is for individuals aged 16 or older with central vision loss from age-related macular degeneration. Participants must have a stable gaze within one degree using their preferred retinal locus (PRL) and be able to calibrate an eye tracker. Those with cognitive impairment, poor fixation, or insufficient central vision loss are excluded.Check my eligibility
What is being tested?
The study measures reading performance in patients with Central Vision Loss. It compares the effectiveness of traditional remapping versus personalized remapping of text to different visual fields in aiding reading.See study design
What are the potential side effects?
Since this trial involves non-invasive techniques like eye tracking and visual tests rather than drugs or surgery, there are no direct side effects associated with the interventions being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can keep my gaze steady using my preferred retinal location.
Select...
I am 16 years old or older.
Select...
I have significant vision loss in the center of my field of view in both eyes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reading Speed for Individual Words
Reading Speed for Natural Text Samples
Reading Speed for Sentences
+3 more
Secondary outcome measures
Eye fixation quality for natural text samples
Eye fixation quality for sentences
Eye fixation quality for words
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Patients with scotomaExperimental Treatment2 Interventions
No remapping (control condition), traditional remapping, personalized remapping
Group II: Normally sighted with artificial scotomaActive Control2 Interventions
No remapping (control condition), traditional remapping, personalized remapping

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,381 Previous Clinical Trials
1,588,667 Total Patients Enrolled
Stephen Engel, Ph.D.Principal InvestigatorUniversity of Minnesota

Media Library

Personalized Remapping Clinical Trial Eligibility Overview. Trial Name: NCT03848663 — N/A
Age-Related Macular Degeneration Research Study Groups: Patients with scotoma, Normally sighted with artificial scotoma
Age-Related Macular Degeneration Clinical Trial 2023: Personalized Remapping Highlights & Side Effects. Trial Name: NCT03848663 — N/A
Personalized Remapping 2023 Treatment Timeline for Medical Study. Trial Name: NCT03848663 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment available for this research endeavor?

"Affirmative, the information located on clinicaltrials.gov confirms that this research project is still seeking participants. The trial was first made available to public view on February 1st of 2022 and has been updated as recently as March 1st of 2022. This initiative requires 108 volunteers from a single location in order to reach its conclusion."

Answered by AI

To what extent has the participant limit been reached for this clinical trial?

"Correct. Clinicaltrials.gov reveals that this clinical research is actively recruiting, with the initial posting being on February 1st 2022 and recent edits occurring March 1st of the same year. A total of 108 patients will be recruited from a single site for participation in the trial."

Answered by AI

What are the proposed outcomes of this investigation?

"This clinical trial's primary objective is to assess the reading speed of participants in a one-day, hour-long session. Secondary outcomes include analysis of eye movements during sentence reading regarding number of leftward (regressive) glances and variability in x and y coordinates for both sentences and natural text samples."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Visual Remapping to Aid Reading With Field Loss
2022. "Visual Remapping to Aid Reading With Field Loss". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03848663.
All > Age Related Macular Degeneration > Macular Degeneration
~23 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top